1. Home
  2. OPRT vs MGNX Comparison

OPRT vs MGNX Comparison

Compare OPRT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oportun Financial Corporation

OPRT

Oportun Financial Corporation

N/A

Current Price

$5.23

Market Cap

238.8M

Sector

Finance

ML Signal

N/A

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

N/A

Current Price

$3.89

Market Cap

220.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OPRT
MGNX
Founded
2005
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
238.8M
220.6M
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
OPRT
MGNX
Price
$5.23
$3.89
Analyst Decision
Buy
Buy
Analyst Count
2
5
Target Price
$7.00
$5.00
AVG Volume (30 Days)
539.4K
703.2K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
127.18
N/A
EPS
0.05
N/A
Revenue
$956,685,000.00
$149,500,000.00
Revenue This Year
$32.79
N/A
Revenue Next Year
$4.47
$3.19
P/E Ratio
$104.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.03
$1.19
52 Week High
$7.73
$4.64

Technical Indicators

Market Signals
Indicator
OPRT
MGNX
Relative Strength Index (RSI) 51.97 48.84
Support Level $5.06 $1.49
Resistance Level $5.67 $4.55
Average True Range (ATR) 0.22 0.24
MACD 0.03 -0.06
Stochastic Oscillator 70.00 11.63

Price Performance

Historical Comparison
OPRT
MGNX

About OPRT Oportun Financial Corporation

Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: